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Treatment outcomes for children with multidrug-resistant 
tuberculosis: a systematic review and meta-analysis
Dena Ettehad, H Simon Schaaf, James A Seddon, Graham S Cooke*, Nathan Ford*
Summary
Background Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, 
accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially 
challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the 
treatment of MDR tuberculosis in children.
Methods We did a systematic review and meta-analysis of published and unpublished studies reporting treatment 
outcomes for children with MDR tuberculosis. We searched PubMed, Ovid, Embase, Cochrane Library, PsychINFO, 
and BioMedCentral databases up to Oct 31, 2011. Eligible studies included ﬁ  ve or more children (aged ≤16 years) with 
MDR tuberculosis within a deﬁ  ned treatment cohort. The primary outcome was treatment success, deﬁ  ned as a 
composite of cure and treatment completion.
Results We identiﬁ  ed eight studies, which reported treatment outcomes for a total of 315 patients. We recorded much 
variation in the characteristics of patients and programmes. Time to appropriate treatment varied from 2 days to 
46 months. Average duration of treatment ranged from 6 months to 34 months, and duration of follow-up ranged 
from 12 months to 37 months. The pooled estimate for treatment success was 81·67% (95% CI 72·54–90·80). Across 
all studies, 5·9% (95% CI 1·3–10·5) died, 6·2% (2·3–10·2) defaulted, and 39·1% (28·7–49·4) had an adverse event. 
The most common drug-related adverse events were nausea and vomiting. Other serious adverse events were hearing 
loss, psychiatric eﬀ  ects, and hypothyroidism.
Interpretation The treatment of paediatric MDR tuberculosis has been neglected, but when children are treated 
outcomes can be achieved that are at least as good as those reported for adults. Programmes should be encouraged to 
report outcomes in children to improve the knowledge base for care, especially as new drugs become available.
Funding None.
Introduction
An estimated 12 million people worldwide have tuber-
culosis, of whom about 650 000 have multidrug-resistant 
(MDR) disease.
1 Childhood tuberculosis is estimated to 
account for 10–15% of the global tuberculosis burden,
2 
and probably accounts for a similar proportion when 
considering only drug-resistant disease. The highest 
rates of paediatric MDR tuberculosis are reported in low-
income countries,
2 and in some regions the incidence of 
MDR tuberculosis has risen sharply in the past two 
decades—eg, in the Western Cape, South Africa, the 
proportion of culture-conﬁ   rmed cases of tuberculosis 
with multidrug-resistance has tripled in the past 15 years 
from 2·3% to 7·3%.
3
MDR tuberculosis is underdetected in children. 
Diagnosis of drug resistance needs mycobacterial 
culture and drug susceptibility testing (DST),
4 but the 
diﬃ   culty in obtaining respiratory secretions, such as 
sputum or gastric aspirates, or specimens of 
extrapulmonary tuber  culosis from young children,
5 
along with the fact that up to half of all children with a 
clinical diagnosis of tuberculosis disease are smear-
negative and culture-negative, makes microbiological 
conﬁ  rmation  challenging.
6 Strict programmatic 
requirements for microbiological conﬁ  rmation of drug 
resistance com  bined with insuﬃ   cient recognition of the 
importance of taking into account DST patterns from 
adult source cases can lead to substantial delays in 
diagnosis and initiation of appropriate treatment.
7 These 
delays could lead to progression of disease, increased 
risk of infectiousness of children, greater risk of disease 
complications such as tuberculous meningitis, and 
higher rates of morbidity and mortality.
8,9
Paediatric drug-resistant tuberculosis is a neglected 
concern, with few children being treated relative to the 
estimated disease burden.
10 WHO guidelines for the 
treatment of drug-resistant tuberculosis in adults are 
based on evidence from meta-analyses of individual 
patients’ data.
11 However, recommendations for children 
are based on expert opinion, drawing on data from case 
series and cohort studies,
12,13 often with small sample sizes. 
Consequently, variation exists in program  matic choices of 
treatment regimens, with the choice of drugs informed by 
previous drug exposure and DST results.
14 Because of 
uncertainties about diagnosis and the best treatment 
regimens, and concerns about the toxic eﬀ  ects associated 
with MDR tuberculosis treatment, health-care providers 
are cautious about treating paediatric MDR tuberculosis.
We did a systematic review and meta-analysis of the 
available evidence for treatment outcomes in children 
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with MDR tuberculosis, and assessed the characteristics 
of patients and studies that could have aﬀ  ected treatment 
success.
Methods
Search strategy and selection criteria
We searched for publications in PubMed, Ovid, Embase, 
Cochrane Library, PsychINFO, and BioMedCentral data-
bases up to Oct 31, 2011. We developed a highly sensitive 
search strategy, using a combination of the search terms 
“tuberculosis”, “multidrug resistance”, “multidrug-
resistant”, “treatment outcomes”, and “children”, both as 
exploded MESH headings and free-text terms. We 
reviewed the bibliographies of all retrieved articles. We 
also searched all electronically available conference 
abstracts from the International Union Against 
Tuberculosis and Lung Disease (2004–11). Authors of 
relevant studies were contacted for clariﬁ  cation  and 
additional information when necessary. We applied no 
language restriction to our search of abstracts.
Two investigators (DE, NF) reviewed all abstracts and 
full-text articles, with ﬁ  nal inclusion decided through 
consensus. In cases of disagreement, consensus was 
achieved through third-party arbitration (GSC), 
including veriﬁ   cation with the study authors when 
needed. Studies were eligible if they included more 
than ﬁ  ve children (aged ≤16 years) within a deﬁ  ned 
treatment cohort. In anticipation of a paucity of data, 
case series of ﬁ  ve or more children were also included. 
Patients meeting the following criteria were viewed as 
having MDR tuberculosis: Patients meeting the 
following criteria were viewed as having MDR 
tuberculosis: the provision of second-line drugs 
together with either clinical evidence of tuberculosis 
and a known contact with MDR disease or conﬁ  rmed 
MDR DST result from a Mycobacterium tuberculosis 
isolate.
Data extraction
We extracted data from the eligible studies independently 
and in duplicate. Our primary outcome was treatment 
success. We recorded treatment outcomes according to 
WHO classiﬁ   cations of treatment success (cure, 
completion, or both), death, and default (deﬁ  ned as all 
patients lost to follow-up).
11 Success was deﬁ   ned as a 
composite of cure and treatment completion as deﬁ  ned 
by the studies. Intermediate outcomes were probable cure 
or failure according to the investigator’s classiﬁ  cation and 
were subsequently added to the success and failure 
categories, respectively. All patients transferred out of the 
reporting treatment facility were regarded as having 
defaulted treatment, consistent with other MDR 
tuberculosis outcome reviews.
15 Secondary outcomes 
were death, defaulting, and adverse events. For each study 
we collected information about the charac  teristics of 
patients (age, HIV status, previous treatment, and drug 
resistance), studies (setting, treatment protocols, average 
number of drugs in the regimen, treatment duration, 
length of follow-up, and whether the treatment was 
individualised or stand  ardised), and study outcome 
deﬁ  nitions. We extracted the following information as 
determinants of study quality that could have aﬀ  ected 
treatment success: delivery of individualised treatment 
regimens guided by DST, use of injectable drugs, 
admission to hospital at the initiation of treatment, 
treatment completion rates, and provision of treatment 
support.
Statistical analysis
We calculated point estimates and 95% CIs for the 
proportion of patients achieving treatment success and 
the frequency of adverse outcomes. Treatment success 
was estimated conservatively, with all treatment defaults 
regarded as treatment failures. We stabilised the variance 
of the raw proportions using a Freeman-Tukey-type 
arcsine square-root transformation
16 and calculated 
pooled estimates using a DerSimonian and Laird 
random-eﬀ  ects model.
17 We ran a sensitivity analysis on 
our primary outcome using a Bayesian random-eﬀ  ects 
model with Monte Carlo Markov chain simulations of 
variability.
18 We calculated the τ² statistic to assess the 
proportion of overall variation attributable to between-
study heterogeneity, because this measure is less 
sensitive to the number of studies,
19 and explored 
potential sources of heterogeneity with univariate 
1815 abstracts identiﬁed and screened for possible inclusion
1758 excluded after screening of abstract and title (inclusion 
           criteria not met)
57 full-text articles screened for eligibility criteria
      31 excluded
            16 were reviews of other studies
              7 did not meet inclusion criteria
              4 had no outcomes
              2 included no children
              1 had no patients with multidrug-resistant tuberculosis
              1 was a selected cohort of tuberculous meningitis 
29 studies assessing the eﬀect of multidrug-resistant 
      tuberculosis treatment on patients’ outcomes
      22 excluded 
            4 did not meet inclusion criteria 
            6 were duplicate reports 
            5 had data not disaggregated by age 
            1 had no paediatric data
            2 had no outcome data 
            1 had data not disaggregated by resistance status 
            2 did not conﬁrm resistance status 
            1 had a selective series of spinal tuberculosis cases
8 studies included in analysis
      1 additional full-text article
         identiﬁed from bibliographies
      2 abstracts identiﬁed from The 
         Union conference abstracts
    1 study included from reanalysis
Figure 1: Study selection processArticles
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sensitivity analyses with χ² to estabish the potential eﬀ  ect 
of the following covariates: DST conﬁ  rmatory testing 
(≤50% or >50% of the cohort), treatment duration 
(≤ 18 months or >18 months), use of injectable drugs 
(≤80% or >80% of the cohort), age (≤ 5 years or >5 years), 
and HIV status (≤30% or >30% of the cohort). All 
p values are two-sided, and a p value of less than 0·05 was 
regarded as signiﬁ   cant. We did analyses using Stata 
(version 12) and MetaAnalyst (version Beta 3.13).
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had ﬁ   nal responsibility for the decision to 
submit for publication.
Results
The eight studies included in our analysis (ﬁ  gure  1) 
came from individual treatment programmes from ﬁ  ve 
countries (Peru,
20 Spain,
21 the USA,
22,23 South Africa,
7,24,25 
and Latvia
26) and reported on treatment outcomes for a 
range of eight patients
21 to 111 patients.
24 One study was a 
conference abstract;
26 the rest were published as full text 
articles.
Studies were done in a range of settings, including 
countries with high
7,21,24,25 and low
17,22,23,26 MDR tuberculosis 
burdens. The median age of children ranged from 
25 months
25 to 132 months
20 and HIV seropositivity 
ranged from 0%
22 to 54% (table 1).
25 In four studies, most 
children were reported to have been in contact with an 
adult with MDR tuberculosis (table 1).
7,20–22 The proportion 
of previously treated patients ranged from 0%
21 to 87%
20 
(table 1).Duration of treatment ranged from 6 months to 
34 months,
22 and in most studies treatment was provided 
for a minimum of 18 months, which is consistent with 
WHO recommendations (table 2).
7,20,22,24 Median duration 
of follow-up, reported by four studies, ranged from 
12 months
25 to 36·7 months (table 2).
7 Time to appropriate 
treatment varied from 2 days
7 to 46 months.
20 All studies 
provided individualised treatment regimens guided by 
DST and reported high rates of treatment completion, 
and most studies
7,20–22,24–26 provided injectable drugs to 
most patients (table 2). For most patients, treatment was 
initiated in hospital (table 2).
7,20,21,23–25 Insuﬃ   cient  data 
were available for outcomes for treatment with extensively 
drug-resistant tuberculosis  to be included in this review.
Across all studies that used second-line drugs in 
individualised protocols (315 children), most children had 
Location Tuberculosis 
prevalence in 
country 
(2010)
1
Total 
conﬁ  rmed 
MDR cases 
in country 
(2010)
1
Setting Median age 
(months 
[range])
Sample 
size
HIV 
positive 
Culture-
positive 
tuberculousis 
Pulmonary 
tuberculosis
Extra-
pulmonary 
tuberculosis
Number 
previously 
treated
Number in 
contact 
with an 
adult with 
MDR 
tuberculosis
Schaaf 
et al 
(2003)
7
Western Cape, 
South Africa
400 000 7386 Hospital and 
clinic
74·4 
(4·8–194·4)
39 6 (15%) 39 (100%) 37 (95%) 18 (46%) 17 (44%)  27 (54%)
Drobac 
et al 
(2006)
20
Lima, Peru 34 000 1048 Ambulatory 
care (after 
initiation)
132 (24–168) 38 2 (5%) 30 (79%) NS 5 (13%) 34 (87%) 27 (71%)
Granich et 
al 
(2005)
23*
California, USA 15 000 92 NA 10 NA NA NA NA NA NA
Mendez 
Echevarria 
et al 
(2007)
21
Madrid, Spain 8400 49 Ambulatory 
care (after 
initiation)
48 (6–180) 8 1 (13%) 5 (63%) 7 (88%) 1 (13%) 0 4 (50%)
Feja et al 
(2008)
22
New York, USA 15 000 92 Chest clinics 
(Department of 
Health sites, 
municipal 
hospital clinics, 
private doctors)
32·4 (0–178) 20 0%† 6 (30%) 16 (80%) 4 (20%) NS 13 (65%)
Leimane 
et al 
(2009)
26
Latvia 970 87 NS NS 76 0 NS NS NS NS NS
Fairlie et al 
(2011)
25
Johannesburg, 
South Africa
400 000 7386 Hospital 25 (5–84) 13  7 (54%) 13 (100%) NS NS 2 (15%) 0
Seddon 
et al 
(2011)
24
Western Cape, 
South Africa
400 000 7386 Hospital and 
clinic
50 (IQR 19–108) 111 43 of 
100 
(43%)
111 (100%) 99 (89%) 38 (34%) 28 (25%) 45 (41%)
Data are number or number (%) unless otherwise stated. MDR=multidrug-resistant. NA=not applicable. NS=not stated. *Additional data provided by authors. †Data available for only three patients.
Table 1: Characteristics of included studiesArticles
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successful treatment (τ² 200·7; ﬁ   gure 2). Our pooled 
estimate changed little when we used a Bayesian approach 
(successful treatment in 80·1% of patients, 95% credible 
intervals 67·0–92·0). In subgroup analysis, treatment 
success was higher for studies in which most patients 
were treated with injectable drugs (87·2%, 95% CI 
Time to 
appropriate 
treatment
Median 
(range) 
number of 
drugs given
Main drugs used Duration of 
treatment
Duration of 
follow-up
Individualised 
treatment 
guided by DST
Number 
(%) of 
injectable 
drugs in 
regimen 
Number (%)
admitted to 
hospital at 
initiation 
Provider of 
directly 
observed 
treatment
Treatment 
support 
provided
Deﬁ  nition of 
cure
Schaaf 
et al 
(2003)
7
2 days if contact 
with MDR 
tuberculosis; 
246 days if drug 
susceptibility of 
source unknown; 
283 days if no 
known source
NS Am, Cfz, Cs, E, 
Eto, H, Km, Ofx, 
S, Thz, Z
9–12 months 
after the last 
positive 
culture, 
depending on 
disease 
severity
Median 14·8 
months (range 
0–36·7) for 
individuals not 
lost to follow-
up before end 
of treatment
Yes (34)  20 (56%) 23 (64%) Health-care 
providers 
or 
community 
volunteers
NS All children 
followed up 
clinically and 
radiologically for 
as long as 
possible; follow-
up cultures 
during and 
towards end of 
treatment to 
conﬁ  rm cure
Drobac 
et al 
(2006)
20
Median 
6·5 months 
(range 0–46)
6·5 (5–9) First-line drugs, 
injectables, 
ﬂ  uoroquinolones
18–24 months 
with at least 
12 consecutive 
months of 
negative 
cultures
NS Yes (28 of 38) 38 (100%) 17 (45%) Nurse or 
community 
health 
worker
Nutritional 
and 
economic 
support
Minimum of 
12 months with 
negative cultures 
and sustained 
radiographical 
and clinical 
improvement 
(weight gain and 
resolution of 
presenting 
symptoms)
Granich 
et al 
(2005)
23*
NS NS NS NS NS NS NS NS NS NS NS
Mendez 
Echevarria 
et al 
(2007)
21
NS NS Am, Cfx, Cs, E, 
Eto, H, Lfx, PAS, Z
15·1 months 
(range 12–18)
Minimum 
18 months 
after diagnosis
Yes (ﬁ  ve from 
the child 
patients and 
three from the 
source case)
5 (63%) All patients 
admitted to 
hospital for 
3 weeks
Nurse Social 
support
All patients 
followed up for at 
least 18 months 
with clinical 
examinations
Feja et al 
(2008)
22
NS 5 (1–12) Cs, Eto, 
quinolones, Z
18·8 (range 
5·7–33·6)
NS Yes (19 of 20) 7 (35%) NS Health-care 
provider or 
outreach 
worker
NS NS
Leimane 
et al 
(2009)
23
NS 5 (4–7) NS 12·5 (range 
10–20)
NS Yes (18 of 76) 74 (97%)  76 (100%) NS NS NS
Fairlie et al 
(2011)
25
2·5 months 
(range 0·3–15)
NS Am, E, Eto, Km, 
Ofx, Z
NS 12 months 
after initial 
investigation
Yes (10 of 13) NS 7 (54%) NS NS Culture-negative 
by 12 months 
(treatment 
continued to end 
of study)
Seddon 
et al 
2011)
24
Median 91 days 
(IQR 51–166); 
58 days if 
MDR tuberculosis 
index cases; 
123 days without 
index case
7 (4–13; for 
patients 
successfully 
treated)
Am, Cs, E, Eto, H, 
Ofx, Trd, Z
 18 months 
(range 8–26) 
for patients 
successfully 
treated
All patients 
followed up for 
1 year after the 
completion of 
treatment
Yes (103 of 
111)
105 (95%) Almost all 
treated 
initially in 
hospital
NS NS Negative results 
of three 
consecutive 
respiratory 
cultures obtained 
at least 1 month 
apart, with no 
positive culture 
results after the 
ﬁ  rst negative 
result
Am=amikacin. Cfx=ciproﬂ  oxacin. Cfz=clofazimine. Cs=cycloserine. E=ethambutol. Eto=ethionamide. DST=drug susceptibility testing. H=isoniazid (given at high dose [15–20 mg/kg bodyweight]). 
Km=kanamycin. Lfx=levoﬂ  oxacin. MDR=multidrug-resistant tuberculosis. NS=not stated. Ofx=oﬂ  oxacin. PAS=para-aminosalicylic acid. S=streptomycin. Thz=thiacetazone. Trd=terizidone. Z=pyrazinamide. 
*Additional data provided by authors.
Table 2: Details of treatment providedArticles
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74·7–99·8%) compared with studies in which injectable 
drugs were used rarely (62·6%, 45·3–80·0%; p=0·02)—
the eﬀ  ect of all other covariates (DST conﬁ  rmatory testing, 
treatment duration, age, and HIV status) on treatment 
success were non-signiﬁ  cant, but the small sample size 
prevents us from making any ﬁ  rm conclusions.
22 deaths were reported across all studies, giving an 
overall pooled proportion of 5·9% (1·3–10·5). 19 children 
were reported to have defaulted from care across all 
studies, giving a pooled proportion of 6·2% (2·3–10·2).
Adverse events, reported by six studies 
(182 patients),
7,20–22,24,26 were common, with a pooled 
Overall
Fairlie et al (2011)25
Schaaf et al (2003)7
Granich et al (2005)23
Drobac et al (2005)20
Seddon et al (2011)24
Feja et al (2008)22
Lemaine et al (2009)23
Mendez Echevarria et al (2007)21
South Africa
South Africa
USA
Peru
South Africa
USA
Country
Latvia
Spain
81·67 (72·54–90·80)
53·58 (28·16–78·05)
53·75 (38·37–68·78)
86·69 (61·55–99·39)
93·65 (83·99–99·05)
79·02 (71·03–86·02)
78·62 (59·04–93·05)
Proportion (95% CI)
91·57 (84·38–96·69)
97·14 (77·30–97·56)
13
39
10
38
111
20
patients
76
8
Number of
7
21
9
36
88
16
events
70
8
Number of
Percentage 
0 20 40 60 80 100
Figure 2: Proportion of patients achieving treatment success
Weighted according to random-eﬀ  ects analysis.
Death
Schaaf et al (2003)7*
Drobac et al (2005)20
Granich et al (2005)23
Mendez Echevarria et al (2007)21
Feja et al (2008)22
Lemaine et al (2009)26
Fairlie et al (2011)25
Seddon et al (2011)24
Overall
Adverse events
Schaaf et al (2003)7
Drobac et al (2005)20
Mendez Echevarria et al (2007)21
Feja et al (2008)22
Lemaine et al (2009)26
Fairlie et al (2011)25
Overall
Default
Schaaf et al (2003)7
Drobac et al (2005)20
Granich et al (2005)23
Mendez Echevarria et al (2007)21
Feja et al (2008)22
Lemaine et al (2009)26
Fairlie et al (2011)25
Seddon et al (2011)24
Overall
South Africa
Peru
USA
Spain
USA
Latvia
South Africa
South Africa
South Africa
Peru
Spain
USA
Latvia
South Africa
South Africa
Peru
USA
Spain
USA
Latvia
South Africa
South Africa
Country
8·71 (2·08–19·28)
3·74 (0·14–11·86)
2·33 (2·01–18·81)
2·86 (2·44–22·70)
6·95 (0·28–21·38)
0·33 (0·30–2·82)
32·09 (11·14–57·84)
12·05 (6·70–18·69)
5·90 (1·32–10·47)
55·41 (39·39–70·87)
42·31 (27·43–57·93)
50·00 (19·61–80·39)
37·45 (13·46–65·36)
34·41 (24·28–45·32)
17·72 (2·95–41·14)
39·05 (28·65–49·44)
21·24 (10·13–35·08)
3·74 (0·14–11·86)
13·31 (0·61–38·45)
16·28 (0·78–45·67)
11·80 (1·86–28·62)
1·89 (0·07–6·11)
17·72 (2·95–41·14)
3·11 (0·72–7·11)
6·20 (2·26–10·15)
Proportion (95% CI)
39
38
10
8
20
76
13
111
36
38
8
11
76
13
39
38
10
8
20
76
13
111
patients
Number of
3
1
0
0
1
0
4
13
20
16
4
4
26
2
8
1
1
1
2
1
2
3
events
Number of
Percentage 
0 20 40 60 80
Figure 3: Secondary outcomes
Weighted according to random-eﬀ  ects analysis. *Study reported one additional death unrelated to tuberculosis.Articles
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proportion of children having an adverse event of 39·05% 
(28·7–49·4; ﬁ   gure 3). In most studies, children were 
screened clinically on a regular basis (of varying regularity 
in the diﬀ  erent studies), with investigations requested if 
any concerns were raised. The most frequently reported 
drug-related adverse event was nausea (table 3). Other 
serious adverse events were hearing loss, psychiatric 
eﬀ  ects, and hypothyroidism. For minor adverse events, 
treatment could largely be continued without the need to 
stop any drugs. For the more severe adverse events, 
treatment with the drug thought to be causing the adverse 
eﬀ  ect was discontinued, and the patient was switched to 
an alternative treatment.
Discussion
Our systematic review suggests that MDR tuberculosis 
can be successfully treated in children, with the overall 
proportion of children achieving treatment success as 
good as, if not better than, that reported for adults 
receiving individualised treatment regimens (64%).
15 
Mortality and defaulting seemed to be lower for children 
than for adults, but these diﬀ  erences were not statistically 
signiﬁ  cant.
Detailed data for adverse events were absent from 
some studies, and adverse events were not systematically 
recorded in most studies. Nevertheless, more than a 
third of children had adverse events. This ﬁ  nding draws 
attention to the urgent need for more eﬀ  ective drugs, 
paediatric formulations of drugs, and a better 
understanding of the best possible dosing in children. 
Previous studies have reported a lower incidence of 
adverse events to second-line drugs in children than in 
adults.
27 In one study,
28 investigators compared 
incidences of adverse events between adults and 
children, recording rates of gastritis and psychiatric 
eﬀ  ects in adults to be about three times that of children 
who received similarly aggressive individualised 
regimens within the same series. We were unable to 
compare the prevalence of adverse events for children 
and adults because summary estimates were not 
available for adults.
15,29
In line with expert opinion
30 and reviews,
31 our subgroup 
analysis suggested that the use of injectable drugs was 
associated with improved treatment outcomes for 
paediatric MDR tuberculosis. The best possible duration 
of treat  ment for MDR tuberculosis is not established, 
and recom  mendations are largely based on expert 
opinion.
30 The duration of treatment reported for children 
in this review was on average less than that reported for 
adults.
15,27 The paucibacillary nature of MDR tuberculosis 
in many children implies that bacillary clearance can be 
faster in children than in adults,
7 although one of the 
studies included in this study had very high rates of 
smear-positive disease, most likely because of progression 
of disease before MDR tuberculosis was diagnosed.
24 
Shortening treatment duration is an important goal for 
MDR tuberculosis management programmes,
32 and 
fewer drugs and shorter treatment durations (12 months 
compared with 18 months for adults) can potentially 
suﬃ   ce in early, non-extensive childhood disease.
33 Future 
research should further assess the potential for shorter 
treatment as a method to limit costs and adverse events, 
Adverse events (n [%]) Drugs potentially implicated
Schaaf et al (2003)
7 Nausea (4 [3%])
Vomiting (17 [44%])
Gastrointestinal discomfort (14 [4·1%])
Ethambutol, ethionamide
Ethambutol, oﬂ  oxacin
Ethionamide
Drobac et al (2006)
20 Gastritis (12 [31·6%])
Loss of high frequency hearing (2 [6·7%])
Nephrotoxicity (asymptomatic creatinine rise; 1 [2·6%])
Psychiatric eﬀ  ects (depression, anxiety, and hallucinations; 4 [10·5%])
Hypothyroidism (3 [7·9%])
Hypersensitivity rash (1 [2·6%])
Hypokalaemia (1 [2·6%])
Ethionamide
Streptomycin
Streptomycin
Cycloserine
Ethionamide
Not stated
Streptomycin
Mendez Echevarria et al 
(2007)
21
Raised creatine kinase (1 [12·5%])
Temporary achilles tendinitis (1 [12·5%])
Abnormality of visual evoked potential without clinical repercussion (1 [12·5%])
Transitory psychosis (1 [12·5%])
Amikacin
Levoﬂ  oxacin
Ethambutol
Cycloserine
Feja et al (2008)
22 Hypothyroidism (1 [9·1%])
Blurred vision (1 [9·1%])
Hearing loss (1 [9·1%])
Muscle pain (1 [9·1%])
Raised liver function test results (1 [9·1%])
Gastrointestinal upset (1 [9·1%])
Loss of appetite and abdominal pain (1 [9·1%])
Ethionamide, para-aminosalicylic acid
Cycloserine
Capreomycin
Capreomycin
Not stated
Not stated
Not stated
Leimane et al (2009)
26 Not stated ··
Fairlie et al (2011)
25 Angioedema (1 [10·0%])
Hearing loss (1 [10·0%])
Rifampicin
Amikacin
Seddon et al (2011)
24 Not stated ··
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especially because improvements in diagnostics might 
increase the number of individuals needing treatment.
34
The average time to initiation of appropriate treatment 
ranged from 2·5 months to 9·2 months, with the long 
delays probably caused by challenges in the conﬁ  rmation 
of diagnosis. Such delays before appropriate treatment 
draw attention to the need to develop rapid, reliable, and 
aﬀ   ordable tuberculosis diagnostics for children.
35 If 
programmes were to treat more children and need less 
stringent proof of MDR tuberculosis, then treatment 
could be started earlier for children, which might improve 
outcomes. For this to happen, substantial changes in 
treatment practices would be needed, whereby children 
with clinical tuberculosis and an MDR contact would be 
initiated on MDR tuberculosis treatment while awaiting 
micro  biological test results with the assumption that the 
disease is likely to be MDR tuberculosis. At present, such 
children are started on ﬁ  rst-line treatment while waiting 
for microbiological drug-resistant conﬁ  rmation or clinical 
failure. However, because available drugs are associated 
with a high frequency of adverse events, such a strategy 
might become more feasible when new, less toxic drugs 
become available.
Our study has several strengths and limitations. 
We used a random-eﬀ   ects analysis and subgroup 
analyses in anticipation of heterogeneity. We also used a 
broad and inclusive search strategy, but cannot rule out 
the risk of publication bias. Several limitations also exist 
in the available evidence base. All studies included in 
our analysis were observational, and thus subject to 
potential bias as a result of unmeasured variables that 
could have aﬀ  ected outcomes, such as level of health-
care provider, and programme inputs (eg, such as 
material and social support for patients). Another 
limitation is that we were able to do a meta-analysis of 
only aggregate data; a meta-analysis of individual 
patients’ data could be expected to provide further 
information about clinical determinants of treatment 
success.
36 The small amount of data from a few published 
paediatric cohorts leads to poor precision of overall 
estimates and limits the generalisability of ﬁ  ndings. 
Nevertheless, the decision to pool data through meta-
analysis was based on the value of the provision of a 
more precise estimate for treatment success compared 
with that reported by individual studies.
37 Programmes 
should be encouraged to report outcomes to improve 
the knowledge base for care, especially because new 
drugs will become available. Although major adverse 
events are likely to be well recorded,
38 under-reporting of 
minor toxic eﬀ  ects in observational studies might lead 
to underestimation in our meta-analysis. Generally, 
however, estimates of the frequency of adverse events 
derived from observational studies are equivalent to 
those reported from trials.
38 Another limitation is the 
diﬃ   culty in identifying the drug that causes a particular 
adverse event, because children were treated with 
multiple drugs with overlapping toxicities.
Our ﬁ   ndings draw attention to the urgent need to 
encourage more reporting of outcomes for children with 
MDR tuberculosis. We identiﬁ  ed several reports that had 
to be excluded because data were not clearly disaggregated 
by age, which was a missed opportunity.
39,40 Furthermore, 
the discrepancies in the recording of study characteristics 
for paediatric treatment regimens draws attention to the 
need for the standardisation of the data collection process 
and reporting in programmes of childhood tuberculosis.
41 
Although substantial progress has been made in the 
harmonisation of the deﬁ  nitions of cure for adult MDR 
tuberculosis during the period covering the included 
studies,
42 the deﬁ   nition is not suitable for paediatric 
disease. The absence of this deﬁ  nition means that study 
comparisons need to be interpreted with caution and that 
a standardised deﬁ   nition is needed to improve the 
comparability of the results of future research and 
programme assessments. Nevertheless, the results of our 
study should provide encouragement to health-care 
providers treating children with MDR tuberculosis that 
successful outcomes can be achieved, possibly with 
greater frequency than for adults.
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